Revenue Performance - Revenue for Q1 2022 was SGD 2,614,000, a decrease of 12.6% compared to SGD 2,993,000 in Q1 2021[14] - The Group's revenue for Q1 2022 was SGD 2,614,000, a decrease of 12.7% compared to SGD 2,993,000 in Q1 2021[107] - Revenue from tissue products was SGD 2,279,000, down 12.6% from SGD 2,609,000 in the same period last year[107] - Revenue for the Relevant Period was $2.6 million, a decrease of 12.7% compared to $3.0 million in the Previous Period[176] - Revenue for the Relevant Period was $2.6 million, a decrease of $400,000 or 12.7% compared to $3.0 million in the Previous Period, primarily due to reduced orders for sanitary paper products from corporate clients impacted by COVID-19[182] Profitability - Gross profit for Q1 2022 was SGD 657,000, down 20.9% from SGD 831,000 in Q1 2021[14] - Profit before taxation for Q1 2022 was SGD 18,000, significantly lower than SGD 205,000 in Q1 2021, representing a decline of 91.7%[14] - Total comprehensive income for the period in Q1 2022 was SGD 18,000, compared to SGD 175,000 in Q1 2021, a decrease of 89.7%[14] - Basic and diluted earnings per share for Q1 2022 were less than SGD 0.01, compared to SGD 0.02 in Q1 2021[14] - Profit for the Relevant Period was $18,000, a decrease of 89.7% compared to the Previous Period, mainly due to changes in other income[156] - Profit attributable to shareholders was $18,000 in the Relevant Period, down from $175,000 in the Previous Period[187] Cost Management - Cost of sales in Q1 2022 was SGD 1,957,000, down from SGD 2,162,000 in Q1 2021, indicating a reduction of 9.4%[14] - Cost of sales amounted to $2.0 million, representing a decrease of $205,000 or 9.5% compared to $2.2 million in the Previous Period, consistent with the overall decrease in revenue[181] - Selling and distribution expenses for Q1 2022 were SGD 361,000, slightly higher than SGD 350,000 in Q1 2021[14] - Selling and distribution expenses amounted to $361,000, an increase of $11,000 or 3.1% compared to $350,000 in the Previous Period, due to additional headcount in the sales team[187] - Administrative expenses in Q1 2022 were SGD 323,000, compared to SGD 384,000 in Q1 2021, a decrease of 15.9%[14] - Administrative expenses were $323,000, a decrease of $61,000 or 15.9% compared to $384,000 in the Previous Period, resulting from a lower administrative headcount[187] Financial Position - The company has net current assets of $2.7 million as of September 30, 2021, providing sufficient funds for working capital requirements[167] - The company has unutilized banking facilities of $3.9 million on standby[169] Operational Insights - The Group's principal activity remains the supply of tissue products to corporate customers in Singapore, with no significant seasonal impact on revenue[106] - The overall strategy during the pandemic is to avoid self-inflicted interruptions to operations, with all employees vaccinated against COVID-19[168] - The company is optimistic about recovering revenue as tissue products are daily necessities[172] - The company will continue to evaluate development opportunities to strengthen its competitive advantage and market-leading position[172] Accounting and Compliance - The Group has adopted all new and revised IFRSs relevant to its operations, with no significant changes to accounting policies reported[99] - The corporate income tax rate applicable to the Group's Singapore subsidiary is 17% on estimated chargeable income[127] - The Group's amortization of software license remained stable at SGD 2,000 for both Q1 2022 and Q1 2021[110] - The Group's depreciation of property, plant, and equipment for Q1 2022 was SGD 1,815,000, a decrease from SGD 1,933,000 in Q1 2021[110] - The total auditor's remuneration for Q1 2022 was SGD 10,000, slightly up from SGD 9,000 in Q1 2021[110] - Interest expenses on bank loans for Q1 2022 were SGD 1,000, consistent with Q1 2021[14] - Interest expenses on lease liability remained unchanged at SGD 2,000 for both Q1 2022 and Q1 2021[14] Impact of COVID-19 - Sales of tissue products decreased by $330,000, representing a decrease of 12.6% due to the effects of COVID-19[177] - Sales of hygiene-related products decreased by $53,000, representing a decrease of 20.2% also due to the effects of COVID-19[178] - Sales of sanitary paper products decreased by $330,000, a decline of 12.6%, attributed to the effects of COVID-19[183] - Sales of sanitary-related products decreased by $53,000, a decline of 20.2%, also due to COVID-19 impacts[184]
日光控股(08451) - 2022 Q1 - 季度财报